Cited by 43Quantum Computing Algorithms and ArchitectureComputational Drug Discovery MethodsAdvanced Chemical Physics Studies

Toward the institutionalization of quantum computing in pharmaceutical research

Zinner, Maximillian, Dahlhausen, Florian, Boehme, Philip, Ehlers, Jan, Bieske, Linn, Fehring, Leonard·2022·Drug Discovery Today

Abstract

Innovative pharmaceutical companies have started to explore quantum computing (QC). In this article, we provide a collective industry perspective from QC domain leaders at leading pharmaceutical companies. There are immediate nonfinancial benefits in engaging with QC, some likely financial returns in the short term in drug development, manufacturing, and supply chain, and potentially large scientific benefits in drug discovery long term. We discuss the required activities for institutionalizing QC: how to create an understanding of QC among researchers and management, which and how to deploy external resources, and how to identify the problems to be addressed with QC. If (and once) deployable, QC will likely have a similar trajectory to that of computer-aided drug design (CADD) and artificial intelligence (AI) during the 1990s and 2010s, respectively.

Integrity signals

Registry

Crossref · 10.1016/j.drudis.2021.10.006

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

1 of the 37 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Zinner, M., Dahlhausen, F., Boehme, P., Ehlers, J., Bieske, L., & Fehring, L.
Affiliations
Witten/Herdecke University (DE)
Corresponding author
Fehring, Leonard
Venue
Drug Discovery Today
Publisher
Elsevier BV
Published
2022-02
Volume
27
Issue
2
Pages
378-383
ISSN
1359-6446 (ISSN-L)
OpenAlex
W3208259513
Cited by
43
References
37
Citations by year
2026: 6 · 2025: 11 · 2024: 11 · 2023: 10 · 2022: 4 · 2021: 1
FWCI
2.29
Type
journal article
Language
en
Open access
closed
Locations
  • Drug Discovery Today (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Physical Sciences › Computer Science › Artificial Intelligence › Quantum Computing Algorithms and Architecture
  • Physical Sciences › Computer Science › Computational Theory and Mathematics › Computational Drug Discovery Methods
  • Physical Sciences › Physics and Astronomy › Atomic and Molecular Physics, and Optics › Advanced Chemical Physics Studies
Keywords
quantum computing, pharmaceutical industry, drug discovery, drug development, institutionalization, quantum computing adoption, computer-aided drug design, artificial intelligence in drug discovery, industry perspectives
MeSH terms
Pharmaceutical Research, Artificial Intelligence, Computing Methodologies, Pharmaceutical Preparations, Humans, Institutionalization, Quantum Theory

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review